Artiva Biotherapeutics, Inc.
ARTV
$11.78
$0.564.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.02% | -0.24% | 9.42% | 28.31% | 42.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.19% | 20.06% | 24.88% | 40.89% | 50.38% |
| Operating Income | -10.19% | -20.06% | -24.88% | -40.89% | -52.99% |
| Income Before Tax | -15.78% | -29.06% | -23.21% | -19.12% | -45.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.78% | -29.06% | -23.21% | -19.12% | -45.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.78% | -29.06% | -23.21% | -19.12% | -45.46% |
| EBIT | -10.19% | -20.06% | -24.88% | -40.89% | -52.99% |
| EBITDA | -10.31% | -20.47% | -25.56% | -42.23% | -54.93% |
| EPS Basic | -14.20% | -28.08% | 4.90% | 96.04% | 95.16% |
| Normalized Basic EPS | -14.21% | -21.95% | 4.90% | 96.04% | 95.16% |
| EPS Diluted | -14.20% | -28.08% | 4.90% | 96.04% | 95.16% |
| Normalized Diluted EPS | -14.21% | -21.95% | 4.90% | 96.04% | 95.16% |
| Average Basic Shares Outstanding | 1.38% | 0.77% | 29.55% | 2,905.28% | 2,905.93% |
| Average Diluted Shares Outstanding | 1.38% | 0.77% | 29.55% | 2,905.28% | 2,905.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |